BB Biotech’s NAV rose 5.6% in CHF in Q3 2026 and the share price 6.
Q3 was slightly ahead of our forecasts, helped by transaction revenue.
We make minor 2026E-28E EPS revisions and keep our fair value range of SEK 44-50 unchanged after a s...
* Q3 was soft on ad hoc sales decline * Structurally declining opex base is encouraging * We lower a...
* Q3 NAV 4% above ABGSCe * Impressive performances by DPP and Safe Life * P/NAV well below historica...
Redeye comments on the outcome of Biovica’s rights issue.
Ependion presented another quarter with strong numbers across the board.
* The merger in focus for now * Q3’26e sales of SEK 516m and adj.
Redeye comments on today’s announcements that Nanologica has updated its strategy, appointed board m...
Redeye comments on Alligator Bioscience’s Q3 report, the first full quarter since the company refocu...
Stark lönsamhet men fortsatt begränsad ARR-utveckling Nettoomsättningen ökade med 10,9 % till 42,3 ...
Enea's net sales fell 5% in Q3 as customers postponed key deals, yet management keeps both its 2026 ...
* Q3'26 numbers due on 4 November at 07:45 CET * Estimate changes reflect India divestment * Fair va...
September’s trading recovery has continued into October, strengthening NAGA’s earnings outlook on a ...
* Q3 sales 11% below ABGSCe SEK 75m * Gross margin up 4.
Redeye considers Björn Borg’s Q3 report better than expected, with net sales 3% above our estimate a...
* Adj. EBITDA-capex SEK 2.3m vs. ABGSCe 3.2m * The miss was entirely ad hoc-driven * Trading at 5x '...
Redeye shares its initial take on Stille's Q3 2026 results.
Redeye shares its initial take on Modelon's Q3 2026 report.
Studsvik reported a solid Q3, with sales above expectations and adjusted EBIT broadly in line, suppo...